Dr. Suresh Veeramani
Department of
Internal Medicine
University of Iowa,
USA
Email: [email protected]
Qualifications
2003 Ph.D., Indian
Veterinary Research Institute, India, Veterinary Immunology
2000 M.Sc., Indian Veterinary Research Institute,
India, Veterinary Immunology
1998 B.Sc., Tamil Nadu Veterinary and Animal Sciences
University, India, Veterinary Science
Publications (Selected)
-
Veeramani, S., Yin, C., Coleman, K. L., & Weiner, G. J. (2025). Technical, intratumoral and interpatient variability of a novel assay that quantifies fractional occupancy of PD1 by PDL1 in clinical biospecimens. Cancer Research, 85(8_Supplement_1), 4646-4646.
-
Ruiz-Ciancio, D., Veeramani, S., Singh, R., Embree, E., Ortman, C., Thiel, K. W., & Thiel, W. H. (2024). AptamerRunner: An accessible aptamer structure prediction and clustering algorithm for visualization of selected aptamers. Molecular Therapy Nucleic Acids, 35(4).
-
Ruiz-Ciancio, D., Lin, L. H., Veeramani, S., Barros, M. N., Sanchez, D., Di Bartolo, A. L., ... & Thiel, W. H. (2023). Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia. Molecular Therapy-Nucleic Acids, 33, 698-712.
-
Narayan, C., Veeramani, S., & Thiel, W. H. (2022). Optimization of RNA aptamer SELEX methods: improved aptamer transcript 3′-end homogeneity, PAGE purification yield, and target-bound aptamer RNA recovery. nucleic acid therapeutics, 32(1), 74-80.
-
Veeramani, S., Blackwell, S. E., Thiel, W. H., Yang, Z. Z., Ansell, S. M., Giangrande, P. H., & Weiner, G. J. (2019). An RNA Aptamer–Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients. Cancer immunology research, 7(9), 1511-1522.
-
Prabhakar, P., Balasubramanian, S., Veeramani, S. R., Mohammad, S. N., Sivakumar, G. S., SathishKumar, S., ... & Selvarani, G. (2017). Incidence of coronary artery anomalies among patients undergoing coronary angiography and its relevance to appropriate choice of coronary catheter selection. Indian Heart Journal, 69, S32-S33.
-
Veeramani, S., Blackwell, S. E., Thiel, W. H., Giangrande, P. H., & Weiner, G. J. (2017). Targeting human T regulatory cells with novel Interleukin 2 alpha-IL2 complex-specific RNA aptamer. Cancer Research, 77(13_Supplement), 1606-1606.
-
Veeramani, S., Blackwell, S. E., Thiel, W. H., Giangrande, P. H., & Weiner, G. J. (2016). Novel IL-2Ralpha (CD25)-binding RNA aptamer to target T regulatory cells. Blood, 128(22), 3697.
-
Veeramani, S., Blackwell, S. E., Thiel, W. H., Giangrande, P. H., & Weiner, G. J. (2015). Generation of T regulatory-cell specific RNA aptamers. Cancer Research, 75(15_Supplement), 5022-5022.
-
Muniyan, S., Chou, Y. W., Tsai, T. J., Thomes, P., Veeramani, S., Benigno, B. B., ... & Lin, M. F. (2015). p66Shc longevity protein regulates the proliferation of human ovarian cancer cells. Molecular carcinogenesis, 54(8), 618-631.
-
Rogers, L. M., Veeramani, S., & Weiner, G. J. (2014). Complement in monoclonal antibody therapy of cancer. Immunologic research, 59, 203-210.
-
Zent, C. S., Taylor, R. P., Lindorfer, M. A., Beum, P. V., LaPlant, B., Wu, W., ... & Witzig, T. E. (2014). Chemoimmunotherapy for relapsed/refractory and progressive 17p13‐deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low‐dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. American journal of hematology, 89(7), 757-765.
-
Veeramani, S., Chou, Y. W., Lin, F. C., Muniyan, S., Lin, F. F., Kumar, S., ... & Lin, M. F. (2012). Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells. Free Radical Biology and Medicine, 53(1), 95-108.
-
Veeramani, S., Wang, S. Y., Dahle, C., Blackwell, S., Jacobus, L., Knutson, T., ... & Weiner, G. J. (2011). Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood, The Journal of the American Society of Hematology, 118(12), 3347-3349.
Profile Details
WoS ResearcherID: P-7838-2019
https://orcid.org/0000-0001-9217-0872
https://weiner.lab.uiowa.edu/meet-our-team
https://scholar.google.com/citations?user=xhz3Lz4AAAAJ&hl=en
https://www.researchgate.net/profile/Suresh-Veeramani